SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 13344.
  • 2
    Stojanov S, McDermott MF. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 2005; 7: 118.
  • 3
    Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol 2006; 18: 10817.
  • 4
    Masson C, Simon V, Hoppe E, Insalaco P, Cisse I, Audran M. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic joint diseases. Joint Bone Spine 2004; 71: 28490.
  • 5
    Dode C, Andre M, Bienvenu T, Hausfater P, Pecheux C, Bienvenu J, et al, and the French Hereditary Recurrent Inflammatory Disorder Study Group. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor–associated periodic syndrome. Arthritis Rheum 2002; 46: 21818.
  • 6
    Haas SL, Lohse P, Schmitt WH, Hildenbrand R, Karaorman M, Singer MV, et al. Severe TNF receptor-associated periodic syndrome due to 2 TNFRSF1A mutations including a new F60V substitution. Gastroenterology 2006; 130: 1728.
  • 7
    Rosen-Wolff A, Kreth HW, Hofmann S, Hohne K, Heubner G, Mobius D, et al. Periodic fever (TRAPS) caused by mutations in the TNFα receptor 1 (TNFRSF1A) gene of three German patients. Eur J Haematol 2001; 67: 1059.
  • 8
    Trost S, Rose CD. Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 2005; 32: 1757.
  • 9
    Hurst M, Hull K, Nicholls D, Ameratunga R. Hereditary periodic fever syndrome sans fever or distinct periodicity presenting with psychosis. J Clin Rheumatol 2005; 11: 32930.
  • 10
    Rudofsky G, Hoffmann F, Muller K, Filser M, Lohse P, Beimler J, et al. A nephrotic patient with tumor necrosis factor receptor-associated syndrome, IgA nephropathy and CNS involvement. Nephrol Dial Transplant 2006; 21: 110912.
  • 11
    Infevers database. URL: http://fmf.igh.cnrs.fr/infevers.
  • 12
    Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69: 30114.
  • 13
    Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott M, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81: 34968.
  • 14
    Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, Draper-Morgan KA, et al. Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor–associated periodic syndrome: differences between cell types. Arthritis Rheum 2004; 50: 26519.
  • 15
    Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108: 13207.
  • 16
    Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, Todd I, et al. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor–associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 2006; 54: 267487.
  • 17
    Minden K, Aganna E, McDermott MF, Zink A. Tumor necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 2004; 63: 13567.
  • 18
    McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 1217.
  • 19
    Pitts SA, Olomolaiye OO, Elson CJ, Westacott CI, Bidwell JL. An MspA1 I polymorphism in exon 1 of the human TNF receptor type I (p55) gene. Eur J Immunogenet 1998; 25: 26970.
  • 20
    Bazzoni F, Gatto L, Lenzi L, Vinante F, Pizzolo G, Zanolin E, et al. Identification of novel polymorphisms in the human TNFR1 gene: distribution in acute leukemia patients and healthy individuals. Immunogenetics 2000; 51: 15963.
  • 21
    Eskdale J, Turestkaya RL, Armstrong C, Kuprash DV, Nedospasov SA, Gallagher G. A polymorphic microsatellite marker in the human p55 TNF receptor, CD120a. Genes Immun 2000; 1: 22830.
  • 22
    Akman-Demir G, Gul A, Gurol E, Ozdogan H, Bahar S, Oge AE, et al. Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association? J Neurol 2006; 253: 92834.
  • 23
    Shinar Y, Livneh A, Villa Y, Pinhasov A, Zeitoun I, Kogan A, et al. Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashkenazi Jewish multiple sclerosis patients. Genes Immun 2003; 4: 197203.
  • 24
    D'Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor–induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54: 9981008.
  • 25
    Ravet N, Rouaghe S, Dode C, Bienvenu J, Stirnemann J, Levy P, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 2006; 65: 115862.
  • 26
    Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, Ploos van Amstel HK, et al. Heterogeneity among patients with tumor necrosis factor receptor–associated periodic syndrome phenotypes. Arthritis Rheum 2003; 48: 263244.
  • 27
    Weinshenker BG, Hebrink D, Wingerchuk DM, Klein CJ, Atkinson E, O'Brien PC, et al. Genetic variants in the tumor necrosis receptor 1 gene in patients with MS. Neurology 1999; 52: 15003.
  • 28
    Poirier O, Nicaud V, Gariepy J, Courbon D, Elbaz A, Morrison C, et al. Polymorphism R92Q of the tumor necrosis factor 1 gene is associated with myocardial infarction and carotid intima-media thickness—the ECTIM, AXA, EVA and GENIC Studies. Eur J Hum Genet 2004; 12: 2139.
  • 29
    Amoura Z, Dode C, Hue S, Caillat-Zucman S, Bahram S, Delpech M, et al. Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease. Arthritis Rheum 2005; 52: 60811.
  • 30
    Probert L, Eugster HP, Akassoglou K, Bauer J, Frei K, Lassmann H, et al. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 2000; 123: 200519.
  • 31
    Hehlgans T, Pfeffer K. The intriguing biology of the tumor necrosis factor/tumor necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115: 120.
  • 32
    Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 46772.
  • 33
    Spuler S, Yousry T, Scheller A, Voltz R, Holler E, Hartmann M, et al. Multiple sclerosis: prospective analysis of TNF-α and 55kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol 1996; 66: 5764.
  • 34
    Bevilacqua MP. Endothelial-leukocyte adhesion molecules [review]. Annu Rev Immunol 1993; 11: 767804.
  • 35
    Klinkert WE, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H. TNF-α receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: an overview [review]. J Neuroimmunol 1997; 72: 1638.
  • 36
    Bachmann R, Eugster HP, Frei K, Fontana A, Lassmann H. Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am J Pathol 1999; 154: 141722.
  • 37
    Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57: 18858.
  • 38
    The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 45765.